Cargando…
Preclinical validation of the small molecule drug quininib as a novel therapeutic for colorectal cancer
Colorectal cancer (CRC) is a leading cause of cancer deaths. Molecularly targeted therapies (e.g. bevacizumab) have improved survival rates but drug resistance ultimately develops and newer therapies are required. We identified quininib as a small molecule drug with anti-angiogenic activity using in...
Autores principales: | Murphy, Adrian G., Casey, Rory, Maguire, Aoife, Tosetto, Miriam, Butler, Clare T., Conroy, Emer, Reynolds, Alison L., Sheahan, Kieran, O’Donoghue, Diarmuid, Gallagher, William M., Fennelly, David, Kennedy, Breandán N., O’Sullivan, Jacintha |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5064353/ https://www.ncbi.nlm.nih.gov/pubmed/27739445 http://dx.doi.org/10.1038/srep34523 |
Ejemplares similares
-
1,4-dihydroxy quininib attenuates growth of colorectal cancer cells and xenografts and regulates the TIE-2 signaling pathway in patient tumours
por: Butler, Clare T., et al.
Publicado: (2019) -
Tumour vasculature immaturity, oxidative damage and systemic inflammation stratify survival of colorectal cancer patients on bevacizumab treatment
por: Noonan, Sinead A., et al.
Publicado: (2018) -
Predicting response to vascular endothelial growth factor inhibitor and chemotherapy in metastatic colorectal cancer
por: Martin, Petra, et al.
Publicado: (2014) -
Combining 1,4-dihydroxy quininib with Bevacizumab/FOLFOX alters angiogenic and inflammatory secretions in ex vivo colorectal tumors
por: Kennedy, Susan A., et al.
Publicado: (2020) -
1,4-dihydroxy quininib modulates the secretome of uveal melanoma tumour explants and a marker of oxidative phosphorylation in a metastatic xenograft model
por: Slater, Kayleigh, et al.
Publicado: (2023)